

Serial No.: 08/459,141
Filed: 2 June 1995

APPENDIX-CLAIMS AS PENDING

10. (Amended) A vaccine comprising a truncated, membrane-free derivative of a membrane-bound polypeptide, said derivative being devoid of membrane-binding domain whereby the derivative polypeptide is free of said membrane, and having exposed antigenic determinants capable of raising neutralizing antibodies against a pathogen, wherein the truncated polypeptide is a derivative of a glycoprotein of a herpes simplex virus type 1 or type 2, and the pathogen is herpes simplex type 1 and/or type 2.

— 11. (Amended) A vaccine according to Claim 10 wherein the truncated polypeptide is a derivative of a glycoprotein D.

12. (Amended) A vaccine according to Claim 10 wherein the truncated polypeptide is a derivative of a glycoprotein C.

13. (Amended) A vaccine according to Claim 10 wherein the truncated polypeptide is a derivative of a glycoprotein C of a herpes simplex virus type 1 and/or type 2.

14. (Amended) A method of producing a vaccine according to any one of Claim 10, 11, 12 or 13 wherein DNA encoding said membrane-bound polypeptide is prepared lacking coding for membrane-binding domain, incorporating the DNA into an expression vector, transfecting a host cell with said vector, and collecting the truncated polypeptide as a secretion product.

15. A method according to Claim 14 wherein the transfected host cell is a stable eukaryotic cell line.

16. A method according to Claim 15 wherein the transfected host cell is a mammalian cell line.

17. A method according to Claim 15 or Claim 16 wherein the cell line is deficient in the production of dhfr and the vector contains a dhfr selectable marker.

— 18. (Amended) A method according to Claim 14 wherein the truncated polypeptide is a glycoprotein D of herpes simplex virus type 1 or type 2.

— 19. A method according to Claim 18 wherein the truncated polypeptide is restricted to the first 300 amino acid residues of the glycoprotein D.

20. The vaccine according to Claim 10 wherein said polypeptide comprises a mixture of glycoproteins.

21. The vaccine according to Claim 20 in which said mixture comprises glycoprotein C and glycoprotein D.

22. (Amended) The vaccine according to Claim 20 wherein said mixture comprises glycoprotein D [and additional effective glycoprotein].

23. (Amended) The vaccine according to Claim 22 wherein said mixture further comprises glycoprotein B [and glycoprotein D].